Roy S. Herbst, MD, PhD, Yale Cancer Center, USA
For patients with advanced squamous NSCLC who have progressed on both chemotherapy and immune checkpoint inhibitors, no reliable later-line standard of care exists. IBI363, a PD-1/IL-2 alpha-biased bispecific antibody fusion protein, is being tested in the MarsLight-11 phase 3 trial as a potential answer to this gap. Dr. Herbst discusses how the alpha-bias mechanism aims to sustain meaningful immune activation while avoiding the systemic toxicity that previously limited cytokine therapy, and what a positive MarsLight-11 result would mean for the future of docetaxel as a benchmark in this setting.